A Phase 3 interventional study of Alendronate and Denosumab in Osteoporosis and Osteopenia, sponsored by Amgen. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.
Among the 64 studies testing denosumab in Osteoporosis, this one is the 4th largest by enrollment, is one of 5 that started in 2006, is one of 24 in phase 3, and was the 6th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Aarhus University Hospital · Sites in Denmark
Ages 40+ · Women only
Chrissy Kistler · Sites in United States
Ages 65+
Wuhan Union Hospital, China · Sites in China
Ages 40+
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25 · Phase 4 19
First in 2002; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,189 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 90 across the 64 interventional studies. Of the 45 that completed or were terminated, 32 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 5th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2006, is one of 18 in phase 3, and was the 6th registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
6 of the studies testing denosumab in Osteoporosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT06332014AmgenEvaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | 2027-01-23 |
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
| NCT04800367Columbia UniversityRomosozumab/Denosumab Study for Premenopausal IOP | 2027-03 |
| NCT07271771Aarhus University HospitalThe Effect of Denosumab on Muscle and Strength and Insulin Sensitivity | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies testing denosumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects receiving alendronate sodium by more than a pre-specified non-inferiority margin.
Inclusion Criteria: - Patient is an ambulatory woman - Patient has BMD value that corresponds to a T-score of less than or equal to -2.0 (g/cm2) at the lumbar spine OR total hip within range specific to the study protocol. Exclusion Criteria: o Any disorder that compromises the ability of the subject to give written and/or to comply with study procedures
Evidence of any of the following per subject report, chart review or central laboratory result:
Hyper- or hypothyroidism; however, subjects on stable thyroid hormone replacement therapy may be allowed per the following criteria:
Elevated transaminases
or poorly tolerant of ALN therapy; contraindications for ALN therapy include:
Oral bisphosphonate treatment:
Administration of any of the following treatments within 3 months of randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this arm will receive active ALN and placebo denosumab
Drug: Alendronate
Subjects in this arm will receive active denosumab and placbo ALN
Drug: Denosumab
ALN; 70 mg; oral; once weekly
60 mg; SC; every 6 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 12 months
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 12 months
Trochanter Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 12 months
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 12 months
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 12 months
First Subject Enrolled: 26-Apr-2006 Last Subject Enrolled: 17-Nov-2006
| Milestone | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Started | 595 | 594 |
| Completed | 553 | 561 |
| Not completed | 42 | 33 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Adverse event | 10 | 8 |
| Withdrew: Withdrawal by subject | 18 | 17 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Ineligibility determined | 1 | 3 |
| Withdrew: Lost to follow-up | 8 | 3 |
| Withdrew: Noncompliance | 2 | 1 |
| Withdrew: Other | 1 | 0 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 | 2.6 (2.4 to 2.8) | 3.5 (3.3 to 3.7) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 | 4.2 (3.9 to 4.5) | 5.3 (5.0 to 5.6) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Trochanter Bone Mineral Density Percent Change From Baseline at Month 12 | 3.4 (3.1 to 3.7) | 4.5 (4.1 to 4.8) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12 | 1.8 (1.5 to 2.1) | 2.4 (2.2 to 2.7) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12 | 0.6 (0.3 to 0.8) | 1.1 (0.9 to 1.4) |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alendronate 70 mg QW | — | 37/586 (6.3%) | 261/586 (44.5%) |
| Denosumab 60 mg Q6M | — | 34/593 (5.7%) | 270/593 (45.5%) |
| Event | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| PneumoniaInfections and infestations | 3/586 | 1/593 |
| DiverticulitisInfections and infestations | 0/586 | 3/593 |
| Non-cardiac chest painGeneral disorders | 2/586 | 1/593 |
| Tibia fractureInjury, poisoning and procedural complications | 2/586 | 1/593 |
| Transient ischaemic attackNervous system disorders | 2/586 | 0/593 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/586 | 2/593 |
| Acute coronary syndromeCardiac disorders | 1/586 | 0/593 |
| BradycardiaCardiac disorders | 1/586 | 0/593 |
| Congestive cardiomyopathyCardiac disorders | 1/586 | 0/593 |
| Coronary artery diseaseCardiac disorders | 1/586 | 1/593 |
| Event | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 56/586 | 75/593 |
| Back painMusculoskeletal and connective tissue disorders | 56/586 | 42/593 |
| NasopharyngitisInfections and infestations | 43/586 | 45/593 |
| InfluenzaInfections and infestations | 42/586 | 41/593 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 37/586 | 31/593 |
| ConstipationGastrointestinal disorders | 31/586 | 36/593 |
| Upper respiratory tract infectionInfections and infestations | 25/586 | 36/593 |
| DyspepsiaGastrointestinal disorders | 29/586 | 34/593 |
| HeadacheNervous system disorders | 32/586 | 30/593 |
| DiarrhoeaGastrointestinal disorders | 20/586 | 30/593 |
| Age Continuous(Years) | Alendronate 70 mg QW | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Mean | 64.6 ± 8.3 | 64.1 ± 8.6 | 64.4 ± 8.5 |
| Sex: Female, Male(Participants) | Alendronate 70 mg QW | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Female | 595 | 594 | 1189 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Alendronate 70 mg QW | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| White or Caucasian | 502 | 502 | 1004 |
| Black or African American | 9 | 7 | 16 |
| Hispanic or Latino | 69 | 66 | 135 |
| Asian | 8 | 6 | 14 |
| Japanese | 4 | 3 | 7 |
| American Indian or Alaska Native | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Other | 3 | 7 | 10 |
No study locations are listed for this record.
The record gives a start of May 2006, a primary completion of Nov 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 2 years 8 months after primary completion. A results delay was requested in Nov 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab